These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 21568730)

  • 21. Alpha 1-antitrypsin: a novel tumor-associated antigen identified in patients with early-stage breast cancer.
    López-Árias E; Aguilar-Lemarroy A; Felipe Jave-Suárez L; Morgan-Villela G; Mariscal-Ramírez I; Martínez-Velázquez M; Alvarez AH; Gutiérrez-Ortega A; Hernández-Gutiérrez R
    Electrophoresis; 2012 Jul; 33(14):2130-7. PubMed ID: 22821488
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification and validation of new autoantibodies for the diagnosis of DCIS and node negative early-stage breast cancers.
    Lacombe J; Mangé A; Jarlier M; Bascoul-Mollevi C; Rouanet P; Lamy PJ; Maudelonde T; Solassol J
    Int J Cancer; 2013 Mar; 132(5):1105-13. PubMed ID: 22886747
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hormone receptors and HER2 expression in primary breast carcinoma and corresponding lymph node metastasis: do we need both?
    Raica M; Cîmpean AM; Ceausu RA; Fulga V; Nica C; Rudico L; Saptefrati L
    Anticancer Res; 2014 Mar; 34(3):1435-40. PubMed ID: 24596391
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lymphocytic infiltrate is associated with favorable biomarkers profile in HER2-overexpressing breast cancers and adverse biomarker profile in ER-positive breast cancers.
    Tsang JY; Hui SW; Ni YB; Chan SK; Yamaguchi R; Kwong A; Law BK; Tse GM
    Breast Cancer Res Treat; 2014 Jan; 143(1):1-9. PubMed ID: 24272079
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characteristics of HER2-positive breast cancer diagnosed following the introduction of universal HER2 testing.
    Pathmanathan N; Provan PJ; Mahajan H; Hall G; Byth K; Bilous AM; Balleine RL
    Breast; 2012 Dec; 21(6):724-9. PubMed ID: 23099207
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Organotropism and prognostic marker discordance in distant metastases of breast carcinoma: fact or fiction? A clinicopathologic analysis.
    St Romain P; Madan R; Tawfik OW; Damjanov I; Fan F
    Hum Pathol; 2012 Mar; 43(3):398-404. PubMed ID: 21840040
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
    Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
    BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relation between hemostatic parameters and prognostic/predictive factors in breast cancer.
    Yigit E; Gönüllü G; Yücel I; Turgut M; Erdem D; Cakar B
    Eur J Intern Med; 2008 Dec; 19(8):602-7. PubMed ID: 19046726
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Moderate level of HER2 expression and its prognostic significance in breast cancer with intermediate grade.
    Ignatov T; Eggemann H; Burger E; Fettke F; Costa SD; Ignatov A
    Breast Cancer Res Treat; 2015 Jun; 151(2):357-64. PubMed ID: 25926338
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A positive role for PEA3 in HER2-mediated breast tumour progression.
    Myers E; Hill AD; Kelly G; McDermott EW; O'Higgins NJ; Young LS
    Br J Cancer; 2006 Nov; 95(10):1404-9. PubMed ID: 17060941
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Polymorphic loci of E2F2, CCND1 and CCND3 are associated with HER2 status of breast tumors.
    Justenhoven C; Pierl CB; Haas S; Fischer HP; Hamann U; Baisch C; Harth V; Spickenheuer A; Rabstein S; Vollmert C; Illig T; Pesch B; Brüning T; Dippon J; Ko YD; Brauch H
    Int J Cancer; 2009 May; 124(9):2077-81. PubMed ID: 19142864
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery and verification of protein differences between Er positive/Her2/neu negative breast tumor tissue and matched adjacent normal breast tissue.
    Weitzel LR; Byers T; Allen J; Finlayson C; Helmke SM; Hokanson JE; Hunsucker SW; Murphy JR; Newell K; Queensland KM; Singh M; Wischmeyer PE; Duncan MW; Elias A
    Breast Cancer Res Treat; 2010 Nov; 124(2):297-305. PubMed ID: 20087651
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor marker phenotype concordance in second primary breast cancer, California, 1999-2004.
    Brown M; Bauer K; Pare M
    Breast Cancer Res Treat; 2010 Feb; 120(1):217-27. PubMed ID: 19629680
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Autoantibody to tumor antigen, alpha 2-HS glycoprotein: a novel biomarker of breast cancer screening and diagnosis.
    Yi JK; Chang JW; Han W; Lee JW; Ko E; Kim DH; Bae JY; Yu J; Lee C; Yu MH; Noh DY
    Cancer Epidemiol Biomarkers Prev; 2009 May; 18(5):1357-64. PubMed ID: 19423516
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bcl-2 is a highly significant prognostic marker of hormone-receptor-positive, human epidermal growth factor receptor-2-negative breast cancer.
    Seong MK; Lee JY; Byeon J; Sohn YJ; Seol H; Lee JK; Kim EK; Kim HA; Noh WC
    Breast Cancer Res Treat; 2015 Feb; 150(1):141-8. PubMed ID: 25682076
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serological immunoreactivity against colon cancer proteome varies upon disease progression.
    De Monte L; Sanvito F; Olivieri S; Viganò F; Doglioni C; Frasson M; Braga M; Bachi A; Dellabona P; Protti MP; Alessio M
    J Proteome Res; 2008 Feb; 7(2):504-14. PubMed ID: 18179166
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinicopathologic Characteristics of Oestrogen Receptor-Positive/Progesterone Receptor-Negative/Her2-Negative Breast Cancer According to a Novel Definition of Negative Progesterone Receptor Status: A Large Population-Based Study from China.
    Li AQ; Zhou SL; Li M; Xu Y; Shui RH; Yu BH; Yang WT
    PLoS One; 2015; 10(5):e0125067. PubMed ID: 25938238
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients.
    Wülfing P; Borchard J; Buerger H; Heidl S; Zänker KS; Kiesel L; Brandt B
    Clin Cancer Res; 2006 Mar; 12(6):1715-20. PubMed ID: 16551854
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of neoadjuvant chemotherapy on HER2/neu status in invasive breast cancer.
    Li P; Liu T; Wang Y; Shao S; Zhang W; Lv Y; Yi J; Wang Z
    Clin Breast Cancer; 2013 Feb; 13(1):53-60. PubMed ID: 23103368
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Active transport of RB protein from the nucleus to the cytoplasm as one of the development mechanisms of HER2-positive breast cancer.
    Kowalik A; Kopczyński J; Wypiórkiewicz E; Góźdź S; Meżyk R; Siedlecki JA
    Pol J Pathol; 2013 Apr; 64(1):9-14. PubMed ID: 23625594
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.